According to Zhitong Finance App, Peger Biopharmaceutical-B (02565.HK) issued an announcement. On November 2, 2026 (after the trading period), the company entered into a placement agreement with the exclusive placement agent. According to this, the company has already agreed to use the exclusive placement agent to place a total of 26.813 million shares to no less than six undertakers at a price of HK$2.985 per share on a best-effort basis. Such placement shares will be issued by the company under general authorization in accordance with the terms and conditions set out in the placement agreement.

According to Zhitong Finance App, Peger Biopharmaceutical-B (02565.HK) issued an announcement. On November 2, 2026 (after the trading period), the company entered into a placement agreement with the exclusive placement agent. According to this, the company has already agreed to use the exclusive placement agent to place a total of 26.813 million shares to no less than six undertakers at a price of HK$2.985 per share on a best-effort basis. Such placement shares will be issued by the company under general authorization in accordance with the terms and conditions set out in the placement agreement.